M. E. Davis-Gardner

CD4+ and CD8+ T cells are required to prevent SARS-CoV-2 persistence in the nasal compartment

This study shows that CD4+ and CD8+ T cells are necessary to prevent SARS-CoV-2 persistence in the nasal compartment but not in the lungs.

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates

This study shows a gorilla adenovirus-based vaccine provides durable immunity against SARS-CoV-2 in both airways of non-human primates, with enhanced protection from aerosol delivery and prime-boost regimens.

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.

mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1

This study evaluates the neutralizing efficacy of bivalent mRNA boosters against emerging SARS-CoV-2 subvariants BA.2.75.2 and BQ.1.1, showing improved protection compared to monovalent boosters.

Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response

The paper identifies three monoclonal antibodies that poorly neutralize the Omicron BA.1 variant, revealing structural and molecular features of antibody evasion.

Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody

This paper identifies and structurally analyzes an antibody that neutralizes SARS-CoV-2 BA.1 and BA.2 variants, revealing its unique epitope and mechanism of action.

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant

This study evaluates the neutralizing activity of mRNA vaccines against the SARS-CoV-2 Omicron variant, showing reduced efficacy after the second dose but improved responses following a third dose.

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

Durability of immune responses to the BNT162b2 mRNA vaccine

This study shows that antibody and T cell responses to the BNT162b2 vaccine wane significantly at 6 months, suggesting a potential need for a third booster dose.

Plasmacytoid dendritic cells produce type I interferon and reduce viral replication in airway epithelial cells after SARS-CoV-2 infection

This study shows that plasmacytoid dendritic cells recognize SARS-CoV-2, produce type I and III interferons, and reduce viral replication in infected airway epithelial cells.

CCR2-dependent monocyte-derived cells restrict SARS-CoV-2 infection

This study identifies a CCR2-dependent monocyte-derived cell mechanism that restricts SARS-CoV-2 infection and inflammation in the lungs of mice.

Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant

The paper compares antibody binding and neutralization against SARS-CoV-2 B.1 and B.1.351 variants in infected and vaccinated individuals, finding reduced titers but retained neutralization.

ISG15-dependent Activation of the RNA Sensor MDA5 and its Antagonism by the SARS-CoV-2 papain-like protease

This study shows ISG15 is essential for MDA5-mediated antiviral responses and is counteracted by SARS-CoV-2's PLpro protease.